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To the editor, 
In a recent review article, there were multiple preventive measures that were proposed for 
the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [1].  Since 2002, we had 
witnessed the emergence of three coronaviruses with a significant impact.  These are the Severe 
Acute Respiratory Syndrome Coronavirus (SARS-CoV), MERS-CoV and the SARS-CoV-2, the 
causative agent of COVID-19.  SARS-CoV-2 emerged in Wuhan, China, in December 2019, and 
according to the World Health Organization (WHO), the global number of cases is 80239 
confirmed as of February 25, 2020 [2].  However, there is no recommended therapy for any of 
these CoVs.   
Remdesivir (with a development code GS-5734) is a broad-spectrum antiviral agent.  
This medication is an experimental drug and had not been licensed or approved at the time of 
writing this article.   It was synthesized and developed by Gilead Sciences in 2017 as a treatment 
for Ebola virus infection.  It is a monophosphoramidate prodrug and is an adenosine analog.  
Remdesivir is metabolizes into its active form, GS-441524, that obscures viral RNA polymerase 
and evades proofreading by viral exonuclease, causing a decrease in viral RNA production.  The 
antiviral mechanism for remdesivir is a delayed chain cessation of nascent viral RNA of Ebola 
virus.  Remdesivir showed antiviral activity against multiple variants of Ebola virus in cell-based 
assays [3] as well as in a rhesus monkey model of Ebola virus disease, [4].  Remdesivir was 
given on a compassionate-use basis to a British nurse who survived Ebola virus disease when she 
relapsed nine months later in the United Kingdom with meningoencephalitis [5].  In a 
randomized controlled trial of Ebola Virus disease therapeutics, 673 participants  received one of 
three monoclonal antibodies (Zmapp, mAb114 or REGN-EB3) or remdesivir [6]. However, the 
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study was stopped as an interim analysis found that individuals who received REGN-EB3 or 
mAb114 had greater survival than either ZMapp or remdesivir [6]. 
In-vitro studies showed that remdesivir can inhibit coronavirus such as SARS-CoV and 
MERS-CoV replication. In an in-vitro test utilizing epithelial cell cultures of a primary human 
airway, remdesivir was effective against bat CoVs, prepandemic bat CoVs, and circulating 
contemporary human CoV in primary human lung cells [7,8].   One study showed that remdesiv 
and interferon beta were superior to lopinavir, ritonavir and interferon beta both in vitro and in 
MERS-CoV mouse model [9].   
With the emergence of the 2019-nCoV (COVID-19), we are in a need for an effective 
antiviral agent to be able to halt the current outbreak.  It had been suggested that remdesivir 
might be an option for the therapy of the COVID-19 patients [10].  In a case report, remdisivir 
reatment with started intravenous on day 7 in a patient with 2019-nCoV (COVID-19) [11].  
Given the broad-spectrum anti-CoV activity of remdesivir demonstrated in pre-clinical studies; a 
randomized, controlled, double blind clinical trial is planned to evaluate the efficacy and safety 
of remdesivir in hospitalized patients with mild or moderate 2019-nCoV respiratory disease [12]. 
This clinical trial has already involved 308 hospitalized adult patients with mild and moderate 
2019-nCoV respiratory disease. The participants were randomized to either placebo or 
remdesivir 200 mg loading dose on day 1 followed by 100 mg iv once-daily as maintenance 
doses for 9 days. The primary outcome was defined as the Time to Clinical recovery (TTCR), up 
to 28 days [12]. TTCR is defined as the time (in hours) from initiation of study treatment (active 
or placebo) until normalization of fever, respiratory rate, and oxygen saturation, and alleviation 
of cough, sustained for at least 72 hours [12].  Another ongoing phase 3 randomized, double-
blind, placebo-controlled, multicenter study is evaluating the efficacy and safety of remdesivir in 
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452 hospitalized adult patients with severe 2019-nCoV respiratory disease [13].  Any clinical 
impact of remdesivir on 2019-nCoV remains unknown, until we get final results of ongoing 
studies. 
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